Literature DB >> 23743689

Should Midazolam Drug-Drug Interactions be of Concern to Palliative Care Physicians?

Aleksandra Kotlinska-Lemieszek1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23743689     DOI： 10.1007/s40264-013-0066-2

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  12 in total

1.  Drug interactions in dying patients: a retrospective analysis of hospice inpatients in Germany.

Authors:  Sebastian Frechen; Anna Zoeller; Klaus Ruberg; Raymond Voltz; Jan Gaertner
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606

2.  The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.

Authors:  J T Backman; K T Kivistö; K T Olkkola; P J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  1998-03       Impact factor: 2.953

3.  Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.

Authors:  S M Tsunoda; R L Velez; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1999-11       Impact factor: 6.875

4.  Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles.

Authors:  Hiroshi Yamazaki; Minako Nakamoto; Makiko Shimizu; Norie Murayama; Toshiro Niwa
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

5.  Interaction between fluconazole and midazolam in intensive care patients.

Authors:  J Ahonen; K T Olkkola; A Takala; P J Neuvonen
Journal:  Acta Anaesthesiol Scand       Date:  1999-05       Impact factor: 2.105

6.  Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.

Authors:  Teijo I Saari; Kari Laine; Kari Leino; Mika Valtonen; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Clin Pharmacol Ther       Date:  2006-04       Impact factor: 6.875

7.  Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

Authors:  K T Olkkola; J T Backman; P J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  1994-05       Impact factor: 6.875

8.  Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.

Authors:  V Hafner; M Jäger; A-K Matthée; R Ding; J Burhenne; W E Haefeli; G Mikus
Journal:  Clin Pharmacol Ther       Date:  2009-11-18       Impact factor: 6.875

9.  A potentially hazardous interaction between erythromycin and midazolam.

Authors:  K T Olkkola; K Aranko; H Luurila; A Hiller; L Saarnivaara; J J Himberg; P J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  1993-03       Impact factor: 6.875

10.  Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin.

Authors:  J T Backman; K T Olkkola; M Ojala; H Laaksovirta; P J Neuvonen
Journal:  Epilepsia       Date:  1996-03       Impact factor: 5.864
View more
  1 in total

1.  Author's Reply to Kotlinska-Lemieszek: "Should Midazolam Drug-Drug Interactions Be of Concern to Palliative Care Physicians?".

Authors:  Sebastian Frechen; Jan Gaertner
Journal:  Drug Saf       Date:  2013-09       Impact factor: 5.606
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.